CL

The article compares Celsius, a high-growth functional energy drink company, against Colgate-Palmolive, a mature consumer staples leader. Celsius shows explosive 85.5% revenue growth but faces risks from Pepsi dependency and has declined 54% over the past year.

Colgate-Palmolive offers defensive stability with consistent dividends (63 consecutive years of increases) and has outperformed the market with a 22% gain. The author recommends Colgate-Palmolive for its reliability and dividend consistency in uncertain economic times.

Colgate-Palmolive is expected to report Q3 2026 earnings of $0.92 per share (up 1.1% YoY) with revenues of $5.33 billion (up 3.9% YoY) on October 30. The company has a positive Earnings ESP of +0.01% with a Zacks Rank #3 (Hold), suggesting it will likely beat consensus estimates. Colgate-Palmolive has beaten EPS estimates in all four of the last quarters.

Colgate-Palmolive is positioned to potentially beat earnings estimates in its upcoming October 30, 2026 report. The company has demonstrated a streak of beating earnings estimates over the last two quarters with an average surprise of 3.16%. With a positive Earnings ESP of +0.01% combined with a Zacks Rank #3 (Hold), the stock has historically shown a ~70% probability of beating consensus estimates when these metrics align.

Procter & Gamble is prioritizing product innovation, AI integration, and brand superiority to accelerate organic sales growth. Key successes include double-digit Baby Care growth in China and Tide's return to growth. Competitors Church & Dwight, Colgate-Palmolive, and Clorox are similarly investing in innovation pipelines and premiumization strategies to strengthen market positions, though PG faces challenges with modest 1% organic sales growth in FY26.

Newell Brands reported Q2 2026 net sales growth of 3% to $2B, marking its first year-over-year growth in four years, driven by innovation and improved retail execution across multiple business units and brands. BJ's Wholesale Club, Church & Dwight, and Colgate-Palmolive also demonstrated strong sales momentum through customer growth, product innovation, and market-share gains, though inflationary pressures and uneven consumer spending remain headwinds.

Colgate-Palmolive, a Dividend King with 63 consecutive years of dividend growth, offers investors a quarterly dividend of $0.53 per share ($2.12 annualized). To generate $1,000 in yearly dividends, investors would need approximately 472 shares, requiring an investment of around $43,240 at the current share price of $91.61.

The stock's ex-dividend date is October 20, with the dividend payable on November 13. With a forward dividend yield of 2.3% and average annual dividend growth of 3.2% over the past decade, the stock represents a stable long-term investment option.

The article recommends four consumer staples companies as long-term dividend investments: Procter & Gamble, Coca-Cola, Colgate-Palmolive, and Hershey. All four have decades of consistent dividend payments, strong brand portfolios, and generate sufficient free cash flow to sustain and grow their dividends through economic cycles.

In a comparison of two major consumer staples companies, Colgate-Palmolive emerges as the stronger investment choice due to its global diversification, consistent growth profile, and strong emerging-market performance. While Clorox offers a cheaper valuation and transformation potential through its GOJO acquisition and ERP improvements, it faces headwinds from elevated inflation, muted demand, and the need to rebuild organic sales momentum.

Colgate-Palmolive is strengthening its market position through innovation, premiumization of oral-care products, and expansion in emerging markets. The company is introducing differentiated products targeting whitening, sensitivity, and gum health, while leveraging its strong global brands.

However, sustaining momentum depends on balancing pricing with volume, successful product launches, and cost management. Colgate trades at a premium valuation (21.5X forward P/E vs. industry 18.4X) with modest EPS growth projected at 4.9% for 2026 and 5.2% for 2027.

McCormick & Company is expected to report Q3 2026 revenues rising 14.7% to ~$2 billion, but earnings may fall 11.8% to 75 cents per share. Growth drivers include the Flavor Solutions segment, pricing actions, and CCI productivity savings, while headwinds include consumer price sensitivity, competitive pressures, and inflationary expenses. The company carries a Zacks Rank #4 (Sell) with a negative Earnings ESP of -1.97%, suggesting limited likelihood of an earnings beat.